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Background: The Second International Conference on Sentinel Node Biopsy in Mucosal
Head and Neck Cancer was hosted by the Department of Otorhinolaryngology, Head and
Neck Surgery of the University Hospital in Zurich, Switzerland, from September 12 to 13,
2003. The aims of this conference were to present the results of validation studies and to
achieve a consensus on methodological requirements.
Methods: More than 80 delegates from 20 countries attended the conference. The presented
validation studies were summarized and compared with the literature. Consensus was achieved
concerning requirements for lymphatic mapping and histopathologic work-up.
Results: Twenty centers presented results on 379 patients with cN0 disease. Sentinel nodes
were identiﬁed in 366 (97%) of 379. Of these 366, 103 (29%) were positive for occult metastasis,
and 263 (71%) were negative. Of those 263 patients, 11 patients (4%) showed nodal disease not
revealed by the sentinel lymph node biopsy (SNB). The negative predictive value of a negative
sentinel node for the remaining neck was 96%. The consensus conference resulted in the use of
a radiotracer, lymphoscintigraphy, and a handheld gamma probe for lymphatic mapping as
minimal requirements. The use of conventional hematoxylin and eosin staining and immu-
nohistochemistry for cytokeratin is mandatory. Step-sectioning of the entire node at intervals
of 150 lm is recommended.
Conclusions: The conference attracted delegates from all over the world, thus underscoring
the high interest in the topic. With regard to the presented data and the data from the
literature, SNB for early oral and oropharyngeal cancer is sufﬁciently validated. The con-
sensus conference resulted in the deﬁnition of minimal methodological requirements for
accurate SNB.
Key Words: Sentinel node biopsy—Elective neck dissection—Micrometastasis—Oral carci-
noma—Head and neck carcinoma.
Since its introduction for malignant melanoma1
and breast cancer,2 sentinel lymph node biopsy
(SNB) has gained popularity in head and neck can-
cer, especially for early lesions of the oral cavity and
the oropharynx.3–8 The First International Confer-
ence on Sentinel Node Biopsy in Mucosal Head and
Neck Cancer, held in Glasgow in 2001, brought
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together more than 80 participants from throughout
the world and summarized promising initial results
from 22 centers.9 Pioneering work has continued in
this ﬁeld, with an increasing number of centers
adopting the technique. Multicenter trials have
commenced to determine the reliability and repro-
ducibility of the technique.10 SNB has been shown to
improve staging in the clinically N0 neck for patients
with early squamous cell carcinoma (SCC) of the oral
cavity and oropharynx.11–13 Other sites, such as the
supraglottic larynx and the hypopharynx, are also
under investigation.14
The Second International Conference on Sentinel
Node Biopsy in Mucosal Head and Neck Cancer was
hosted by the Department of Otorhinolaryngology,
Head and Neck Surgery of the University Hospital in
Zurich, Switzerland, from September 12 to 13, 2003.
More than 80 delegates from 20 diﬀerent countries
attended the conference, thus conﬁrming the contin-
uing high interest in this topic. The aims of this
conference were to present updated results and
technical innovations during the free paper session
and to achieve a consensus on most methodological
aspects of SNB by means of keynote lectures and case
discussions. This article summarizes the results and
provides a consensus review regarding the future of
SNB in the management of the clinically N0 neck in
head and neck SCC.
RESULTS OF THE CONFERENCE
The following results are an analysis of all 20
centers that contributed to the second SNB confer-
ence. Most centers performed SNB followed by
elective neck dissection irrespective of the histological
evaluation of the sentinel lymph node (SLN). The
pathologic characteristics of the SLNs were subse-
quently compared with those of the neck dissection.
Three centers had performed SNB only to stage the
neck. In these cases, a therapeutic neck dissection was
performed only if the SLN was positive, and no
further treatment to the neck was performed if the
SLN was negative. Only centers that performed de-
tailed analysis of the SLN, including immunohisto-
chemistry and step serial sectioning, were included in
the data analysis.
Three hundred seventy-nine patients with clinically
N0 disease were included. SLNs were identiﬁed in 366
(97%) of 379. Of these 366 patients, 103 (29%) were
staged positive for occult lymph node metastasis with
SNB, and 263 (71%) were staged negative. Four pa-
tients had bilateral positive SLNs. Of the 263 patients
staged SLN negative, 11 patients (4%) showed nodal
disease in the neck dissection specimen or, in cases in
which the neck was not further explored after nega-
tive SNB, developed subsequent nodal disease. The
negative predictive value of a negative SLN for the
remaining necks was therefore 96%. Of the 103 pa-
tients staged positive with SNB, 85 (83%) of 103 were
upstaged because of routine hematoxylin and eosin
(H&E) staining, whereas 18 (17%) of 103 were up-
staged because of the additional use of immunohis-
tochemical staining.
DISCUSSION
Results of the Conference and Overview of the
Literature
The principles of SNB are universally accepted as
follows. According to the deﬁnition by the Interna-
tional Union Against Cancer,15 the SLN is the ﬁrst
lymph node to receive lymphatic drainage from a
primary tumor. There might be more than one SLN
for a speciﬁc tumor. If lymphatic spread occurs, the
SLNs are the ﬁrst involved. Other nodes should be
involved only subsequently. The SLNs can be iden-
tiﬁed by peritumoral injection of a radioactive tracer.
The tracer mimics lymphatic spread and accumulates
in the ﬁrst-echelon node. With the help of lympho-
scintigraphy and a gamma probe, the SLNs can be
localized and selectively excised. Histological evalu-
ation of the SLN detects possible clinically occult
metastasis and allows for histological staging of the
neck. In head and neck SCC, most centers have
performed SNB within the context of an elective neck
dissection; this has resulted in upstaging of the N0
neck in a considerable number of cases. Several cen-
ters have now adopted SNB alone as a means of
staging the clinically N0 neck. In these cases, only
patients with a pN+ neck, as assessed by SNB,
warrant further treatment by formal neck dissection.
Patients with negative SNB ﬁndings would receive no
further treatment to the neck. It is recommended that
centers should perform at least 10 cases of SNB in the
context of an elective neck dissection before using
SNB alone as a staging tool.9
The cumulative results of all those who contributed
to the conference conﬁrm the high accuracy of SNB
for early oral and oropharyngeal SCC, as previously
reported in the literature. With an SLN detection rate
of 97%, the technical feasibility has been well dem-
onstrated. The 96% negative predictive value of a
negative SLN underlines the high reliability of the
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technique. As with any other novel technique, SNB
has to be validated for its technical feasibility and the
accuracy of the results. Technical feasibility means
the likelihood of detecting an SLN by means of
lymphoscintigraphy and intraoperative use of a
handheld gamma probe. Validation for accuracy of
the results implies comparison with a standard of
reference—in case of SNB, elective neck dissection.
Most published studies so far are validation studies.
For a summary of the literature on SNB validation in
conjunction with an elective neck dissection, we per-
formed a MEDLINE search. With respect to the
well-known learning curve,9 only studies including
more than 10 patients with SCC of the oral cavity,
oropharynx, or both were selected. Nodal disease had
to be excluded by computed tomography, magnetic
resonance imaging, or ultrasonography. Lympho-
scintigraphy with a radiotracer for lymphatic map-
ping was mandatory; the use of blue dye, optional.
We collected 9 articles5–8,14,16–19 that met these
inclusion criteria with a total of 243 N0 patients. The
results are listed in Table 1. The mean SLN detection
rate was 97% (range, 90%–100%), and the negative
predictive value of a negative SLN for the remainder
of the neck was 96% (range, 88%–100%). This liter-
ature overview, in conjunction with the reported re-
sults of the conference, proves the high reliability and
accuracy of SNB and suggests that SNB can be used
as a staging tool in the future.
To answer the question of validation with a mul-
ticenter prospective study, the American College of
Surgeons Oncology Group in 2003 opened a patho-
logic validation trial for patients with T1 and T2
clinically and radiologically N0 SCCs of the oral
cavity. The evolution of management of oral cancer
in North America has been in such a manner that the
‘‘watchful waiting’’ approach to the N0 neck has
gradually fallen into disfavor, particularly for tongue
and ﬂoor-of-mouth cancers, and there is a strong
standard favoring elective neck dissection for the
clinically negative neck. This trial, therefore, was
designed with the introduction of radiological lym-
phoscintigraphy followed by resection of the oral
cancer, sentinel lymphadenectomy, and immediate
selective neck dissection of levels I through IV. The
end point of the trial is the pathologic comparison of
the SLN with the completion neck dissection speci-
men. Multiple sections and immunohistochemistry
for cytokeratin are performed on the SLN and on the
largest node from each level of the neck dissection
specimen. Surgeon education and credentialing, to
ensure technical standardization of the procedure, is
a strong component of the trial. Quality control with
independent audits and oversight, according to the
standards of the National Cancer Institute, is an
important component as well. The goal is to produce
statistically signiﬁcant data regarding the false-nega-
tive rate of a negative SNB and the overall accuracy
of the SNB procedure and to set the stage for a future
randomized survival trial of SNB (without further
dissection if the SLN is negative) versus planned
initial elective neck dissection. The number of pa-
tients estimated necessary to achieve a statistically
signiﬁcant result was estimated at 160 to achieve a
90% conﬁdence interval. The trial is accruing well,
and the termination of accrual is expected for the end
of the year 2005. Results are not available until the
end of the study to prevent the introduction of bias.
To date there have been no signiﬁcant complications
related to the SLN procedure.
TABLE 1. Summary of the literature review
Author na SLNb Pos SLNc Neg SLNd FN SLNe NPVf (%)
Civantos6 18 18 10 8 1 88
Werner14 55 55 9 46 2 96
Kovacs16 15 15 1 14 1 93
Mozzillo8 41 39 4 35 1 97
Pastore19 20 20 5 15 0 100
Pitman17 20 19 2 17 0 100
Shoaib18 40 36 16 20 1 95
Barzan7 15 14 3 11 1 91
Stoeckli13 19 19 6 13 0 100
SLN, sentinel lymph node; Pos, positive; Neg, negative; FN, false negative; NPV, negative predictive value.
a Number of patients.
b Number of patients with successful detection of an SLN.
c Number of patients with occult disease in the SLN.
d Number of patients without occult disease in the SLN.
e Number of patients with false-negative sentinel lymph nodes, i.e., negative SLNs but occult disease in the neck dissection specimen.
f Negative predictive value of a negative SLN for the remainder of the neck.
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In Europe, where most of the published validation
data come from, the protocol for a prospective
observational trial has been developed in Cannies-
burn. In this trial, patients are not randomized to
receive either SNB or elective neck dissection because
of the high number of patients necessary in such a
study to reach signiﬁcant statistical power. The aim
of the study is to prove that SNB does not achieve
results worse than those expected with elective neck
dissection. Patients with oral and oropharyngeal SCC
of the categories T1 and T2 are enrolled. All patients
undergo SNB, followed by neck dissection only in
case of occult metastasis in the SLN. Preliminary
results included 134 T1/2 tumors of the oral cavity or
oropharynx in clinically N0 patients. In 93% of pa-
tients, an SLN was identiﬁed. Upstaging of disease
occurred in 34%. The negative predictive value of the
technique with a mean follow-up of 24 months was
97%. The preliminary results of this multicenter trial
concluded that SNB can be successfully applied to
early T1/2 tumors of the oral cavity or oropharynx in
a standardized fashion by centers worldwide.
Consensus Discussion on Indications for and
Techniques of SNB
Indications for SNB
Most validation studies so far have published re-
sults from SNB for early oral and oropharyngeal
SCC. These two sites are commonly accessible for
tracer injection with the patient awake, thus allowing
for preoperative lymphoscintigraphy. Larger tumors
are diﬃcult to completely surround by the tracer
injection and are more likely to drain to more than
one lymphatic basin. Furthermore, formal neck dis-
section is often required to obtain adequate access for
resection or reconstruction of larger tumors.
Sites other than the oral cavity and oropharynx
and tumor categories other than T1 and T2 are cur-
rently under investigation in diﬀerent institutions but
generally lack enough validation of data to be uni-
versally recommended. Currently, there are three
accepted indications for SNB in early oral/oropha-
ryngeal SCC: (1) staging of the ipsilateral neck in
unilateral cT1/2 cN0 tumors, (2) staging of the ipsi-
lateral and contralateral neck in midline tumors or
tumors crossing the midline (cT1/2 cN0), and (3)
staging of the contralateral neck in midline tumors or
tumors crossing the midline (cT1/2 cN+; ipsilateral).
Radiological evaluation with computed tomogra-
phy, magnetic resonance imaging, or ultrasonogra-
phy may become mandatory for clinical staging of
the neck before SNB to exclude patients with a high
probability of nodal disease. SNB in an unrecognized
N+ neck is likely to result in a false-negative result
because replacement of the SLN stroma by tumor
inﬁltration may block and reroute the lymphatic
drainage to a non-SLN.
Lymphatic Mapping
The technique of lymphatic mapping may vary
among institutions as a result of diﬀerences in
radiotracer availability and scanning equipment. It is
interesting to note that the published results with
regard to the SLN detection rate are comparable
between diﬀerent techniques once the learning curve
has been overcome. Minimal requirements for lym-
phatic mapping are the use of a radiotracer for pe-
ritumoral injection and the availability of a handheld
gamma probe for intraoperative localization of the
SLN. Preoperative lymphoscintigraphy is highly
recommended because it facilitates SLN localization
and increases the probability of SLN detection. The
experience with blue dye as an adjunct to radiotracer
is controversial, and its use is optional. The sole use
of a blue dye without radiotracer is discouraged be-
cause of very poor SLN identiﬁcation rates. Selection
of the radiotracer, performance of dynamic or static
lymphoscintigraphy, and type of gamma probe are
dependent on every institutions possibilities. It is of
paramount importance that any institution starting
with SNB perform a validation study of the technique
in conjunction with elective neck dissection. Only if
the results are comparable to those in the literature
can the learning curve be considered as overcome and
the technique of lymphatic mapping as reliable.
Histological Work-Up
Thorough histological work-up of the SLNs is
crucial and surpasses by far what is routine for lymph
node assessment in most pathology units. The ﬁxed
node is dissected free of fat and bisected through the
largest axis. If the slices of the halved nodes are
thicker than approximately 2.5 mm, then they should
be further divided into slices of 2.5 mm. Step serial
sectioning of the entire SLN and combined conven-
tional H&E and immunohistochemical staining are
mandatory. The current recommendation is step se-
rial sectioning of the entire SLN at 150-lm intervals.
At each step, four adjacent sections are mounted. At
each level, one section is stained by H&E and one by
immunohistochemistry for cytokeratin. The addi-
tional two serial sections are retained for repeat or
further studies. If no cytokeratin positivity is found,
then the node is declared tumor free. If cytokeratin
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positivity is found, then the positive section is com-
pared with the immediately adjacent serial section
previously stained with H&E to determine whether
the positivity is due to the presence of viable tumor
cells. By using the recommended technique, all
metastases and micrometastases should be identiﬁed.
Intraoperative assessment by frozen section is
controversial. Although immediate analysis, oﬀering
the possibility of performing a neck dissection during
the same procedure in case of a positive SLN, is
desirable, many pathologists are afraid that the fro-
zen-section procedure will result in a considerable
loss of tissue, thus making deﬁnitive assessment of the
remaining lymph node less reliable. Our preliminary
unpublished experience in Zurich and the published
data from a few studies20,21 suggest that frozen-sec-
tion analysis of the SLN is accurate and can be reli-
ably used for immediate intraoperative treatment
decisions. Nevertheless, further data are needed in
this ﬁeld, and, therefore, no recommendation as to
the intraoperative frozen-section examination of
SLNs can be provided to date.
Reporting
The more precisely the lymph nodes from a neck
dissection are examined, the more metastases will be
found.22–24 Because SLNs have to be worked up very
thoroughly, a fairly high number of clinically inap-
parent metastases are expected to be revealed. Many
authors use the term micrometastasis for any metas-
tasis detected by histological work-up of a clinically
N0 neck. However, histologically detected metastases
in a cN0 neck are by deﬁnition occult metastases.
According to Hermanek et al.,25 occult metastases are
further subdivided into isolated tumor cells (ITCs),
micrometastases, and (macro)metastases. Differenti-
ation between micrometastases and metastases is
performed by size. Micrometastases are by deﬁnition
smaller than 2 mm; macrometastases are larger than 2
mm. ITCs have been deﬁned in the 6th edition of the
tumor-node-metastasis classiﬁcation of malignant
tumors as
[S]ingle tumor cells or small clusters of cells not
more than 0.2 mm in greatest dimension that are
usually detected by immunohistochemistry or
molecular methods, but which may be veriﬁed
with H&E stains. ITC do not typically show
evidence of metastatic activity (e.g., proliferation
or stromal reaction) or penetration of vascular or
lymphatic sinus walls.15
Because these three subtypes of occult metastases
might have diﬀerent prognostic value and/or eﬀects
on treatment, they have to be diﬀerentiated and
separately reported by the pathologist, as indicated
by the International Union Against Cancer tumor-
node-metastasis classiﬁcation (6th edition).
In the 6th edition of the tumor-node-metastasis
classiﬁcation of malignant tumors released in 2002, a
deﬁnition of the SLN and proposals for classiﬁcation
were introduced. Classiﬁcation of tumors evaluated
by SNB has to be performed according to these cri-
teria. When SNB is attempted, it has to be indicated
by the addition of the designation (sn) after the N
stage. Cases with ITC are classiﬁed as pN0 (i+) (sn);
those with a micrometastasis are classiﬁed as pN1
(mi) (sn). Exact classiﬁcation is pivotal to avoid stage
migration when comparing the results of treatment
with the results of historical cohorts.
Eﬀect on Treatment
Formal neck dissection according to the primary
tumor site is mandatory in all cases of positive SNB,
irrespective of the type and size of occult metastases,
because the probability of further metastasis is high.5
Adjuvant radiation should be discussed in cases of
multinodal macrometastatic disease or extracapsular
spread according to each institutions guidelines. The
beneﬁt of adjuvant radiation for micrometastatic
disease and ITCs is questionable because of a lack of
evidence. Therefore, no recommendations are possi-
ble.
CONCLUSIONS
Delegates from 20 diﬀerent countries discussed
technical aspects and clinical results at the Second
International Conference on Sentinel Node Biopsy in
Mucosal Head and Neck Cancer in Zurich, Switzer-
land, from September 12 to 13, 2003. The reported
results conﬁrmed the high accuracy and reliability of
SNB for early oral and oropharyngeal SCC. The
conference participants agreed on a consensus that
suggested regulations for the future use of SNB.
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